Multiple Targets on the Gln3 Transcription Activator Are Cumulatively Required for Control of Its Cytoplasmic Sequestration

Rajendra Rai, Jennifer J. Tate, and Terrance G. Cooper
Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee 38163

ABSTRACT
A remarkable characteristic of nutritional homeostatic mechanisms is the breadth of metabolite concentrations to which they respond, and the resolution of those responses; adequate but rarely excessive. Two general ways of achieving such exquisite control are known: stoichiometric mechanisms where increasing metabolite concentrations elicit proportionally increasing responses, and the actions of multiple independent metabolic signals that cumulatively generate appropriately measured responses. Intracellular localization of the nitrogen-responsive transcription activator, Gln3, responds to four distinct nitrogen environments: nitrogen limitation or short-term starvation, i.e., nitrogen catabolite repression (NCR), long-term starvation, glutamine starvation, and rapamycin inhibition of mTorC1. We have previously identified unique sites in Gln3 required for rapamycin-responsiveness, and Gln3-mTor1 interaction. Alteration of the latter results in loss of about 50% of cytoplasmic Gln3 sequestration. However, except for the Ure2-binding domain, no evidence exists for a Gln3 site responsible for the remaining cytoplasmic Gln3-Myc13 sequestration in nitrogen excess. Here, we identify a serine/threonine-rich (Gln3477–493) region required for effective cytoplasmic Gln3-Myc13 sequestration in excess nitrogen. Substitutions of alanine but not aspartate for serines in this peptide partially abolish cytoplasmic Gln3 sequestration. Importantly, these alterations have no effect on the responses of Gln3-Myc13 to rapamycin, methionine sulfoximine, or limiting nitrogen. However, cytoplasmic Gln3-Myc13 sequestration is additively, and almost completely, abolished when mutations in the Gln3-Tor1 interaction site are combined with those in Gln3477–493 cytoplasmic sequestration site. These findings clearly demonstrate that multiple individual regulatory pathways cumulatively control cytoplasmic Gln3 sequestration.

KEYWORDS
Gln3, mTorC1, methionine sulfoximine, nitrogen limitation, rapamycin

A simple rain shower can convert a lush environment inhabited by a Saccharomyces cerevisiae yeast cell into a barren landscape, or anything in between, depending on its severity. Coping with such changes requires a rapid response that is adequate but not excessive. Given these demands, it is not surprising that Gln3 and Gat1, the nitrogen-responsive GATA-family transcription activators, are finely regulated and rapidly responsive (Cooper 2004; Broach 2012; Conrad et al. 2014). In lush nitrogen-replete conditions, Gln3 and Gat1 are cytoplasmic, and the transcription they mediate highly repressed (Figure 1). Cytoplasmic sequestration correlates with formation of complexes with the negative nitrogen regulator Ure2 (Blinder et al. 1996; Bertram et al. 2000; Carvalho and Zheng 2003). As nitrogen becomes limiting, or only poorly transported, or catabolized nitrogen sources are to be found, Gln3 and Gat1 move into the nucleus and robustly transcribe genes encoding the catabolic enzymes and transport systems needed to broadly scavenge poor, derepressive nitrogen sources. This overall regulatory phenomenon has long been designated nitrogen catabolite repression (NCR) (Cooper 1982).

Rapamycin, an inhibitor of the mechanistic target of rapamycin (mTor)—a serine/threonine protein kinase complex (mTorC1)—aberrantly elicits Sit4 phosphatase-dependent Gln3 dephosphorylation,
nuclear localization, and Gln3-mediated transcription in nitrogen-rich medium (Figure 1, right yeast pathway) (Beck and Hall 1999; Cardenas et al. 1999; Hardwick et al. 1999; Bertram et al. 2000). These correlations led to the conclusion that NCR-sensitive Gln3 regulation was mediated by mTor activity, Gln3 being cytoplasmic when mTorC1 activity was high, and nuclear when it was low or inhibited by rapamycin.

In nitrogen excess, mTorC1 is activated in an amino acid- and Gtr-Ego complex-dependent manner (Figure 1, left yeast pathway) (Binda et al. 2009, 2010; Zhang et al. 2012; Jeong et al. 2012). Activated mTorC1 phosphorylates Gln3 and Tor associated protein, Tap42, which, in turn, interacts with TorC1, PP2A, and Sit4 phosphatases, (Di Como and Arndt 1996; Jiang and Broach 1999). mTorC1-bound Tap42-Sit4 and Tap42-PP2A complexes are inactive and unable to dephosphorylate Gln3 (Figure 1, left yeast pathway) (Di Como and Arndt 1996; Beck and Hall 1999; Bertram et al. 2000; Wang et al. 2003; Diaval et al. 2003; Yan et al. 2006). Correlating with these events, Gln3 complexed with Ure2 is sequestered in the cytoplasm. However, even under these conditions, a small amount of Gln3 continues to enter the nucleus, but can exit from it without binding to its target GATA sequences in NCR-sensitive promoters (Rai et al. 2015).

Under nitrogen-limiting conditions, the Gtr-Ego complex cannot activate mTorC1 (Rousselet et al. 1995; Neklesa and Davis 2009; Spieletow et al. 2010; Wu and Tu 2011; Bonfils et al. 2012; Panchaud et al. 2013a, 2013b; Laxman et al. 2014). These conditions, or rapamycin treatment, permits release and activation of the Tap42-Sit4 complex from mTorC1, and dephosphorylation of Gln3. (Figure 1, right yeast pathway) (Yan et al. 2006). Gln3 dissociates from the Gln3-Ure2 complex, cycles into the nucleus and activates transcription (Figure 1, right yeast pathway) (Carvalho and Zheng 2003).

Three observations indicated that NCR-sensitive regulation was more complicated than previously envisioned: (i) Gln3 phosphorylation in nutrient limitation and starvation differed from those generated by rapamycin inhibition of mTorC1 (Cox et al. 2004a). (ii) Sit4-dependent Gln3 dephosphorylation was higher in repressive nitrogen-replete medium than in derepressive nitrogen-limiting conditions, the opposite of its predicted behavior (Tate et al. 2006). (iii) Rapamycin-elicited, Sit4-dependent, Gln3 dephosphorylation was insufficient for nuclear Gln3 localization in strains lacking PP2A phosphatase (Tate et al. 2009, 2010).

While these unexpected observations raised questions about the mechanism of NCR-sensitive Gln3 regulation, it was not until the six independent methods routinely and interchangeably used to down-regulate mTorC1 activity were simultaneously analyzed with a single reporter, Gln3-Myc13, that the full complexity of overall nitrogen-responsive regulation was appreciated (Tate and Cooper 2013). The six methods were clearly not physiologically equivalent as had been tacitly accepted, because each one exhibited a specific Gln3 response with unique, hierarchal phosphatase requirements (Tate and Cooper 2013). Further, in nitrogen excess, Gln3 relocated to the cytoplasm in the absence of Gtr-Ego complex components required for mTorC1 kinase activation (Figure 1) (Tate et al. 2015a). These observations cumulatively demonstrated that Gln3 localization and function were controlled in a highly complex manner involving multiple regulatory pathways.

To deconvolve the complex regulation of Gln3, we needed probes that isolated the individual mechanisms of regulation. To achieve this goal, we reasoned that the existence of multiple regulatory pathways predicted corresponding targets for each of them on the Gln3 molecule.

Figure 1 Schematic summarizing nitrogen-responsive regulation of the mTorC1 kinase complex and downstream control of Gln3 localization in nitrogen excess (left pathway) or limitation (right pathway).
| Plasmid  | Residue Alterations | Primer Sets |
|---------|---------------------|-------------|
| pRR536  | Wild Type Gln3.1-730-Myc | 5'-CGCGGATCCCTATACCAAAATTATTTACCAATCCTATTGCTGCAATTTGCT-3' |
|         |                     | 5'-ATTCCCGGCGGACGTGAAGTACCTCCTGCTATGATTTTCCG-3' |
| pRR676  | Gln3S479A,S480A,S483A,S484A-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR678  | Gln3S479D,S480D,S483D,S484D-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR680  | Gln3S479A,S480A,S483A,S484A,S491A,S492A,S493A,S494A,S496A,S497A-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR682  | Gln3S479D,S480D,S483D,S484D,S486D,S487D,S490D,S491D,S492D,S493D,S495D,S496D,S497D-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR962  | Gln3S479A,S480A-S483A,S484A,S491A,S492D,S493D,S495D,S496D,S497D-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR964  | Gln3S479A,S480A,S483A,S484A,S491A,S492A,S493A,S495A,S496A,S497A-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR1043 | Gln3S479A,S480A,S483A,S484A,S491A,S492A,S493A-S495A,S496A,S497A-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR1040 | Gln3S479A,S480A,S483A,S484A,S491A,S492A,S493A-S495A,S496A,S497A-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR1172 | Gln3S479A,S480A,S483A,S484A,S491A,S492A,S493A-S495A,S496A,S497A-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR1173 | Gln3S479A,S480A-S483A,S484A,S491A,S492A,S493A,S495A,S496A,S497A-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR1178 | Gln3S479A,S480A-S483A,S484A,S491A,S492A,S493A,S495A,S496A,S497A-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR1180 | Gln3S479A,S480A-S483A,S484A,S491A,S492A,S493A,S495A,S496A,S497A-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR1264 | Gln3S479A,S480A-S483A,S484A,S491A,S492A,S493A,S495A,S496A,S497A-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR1266 | Gln3S430D,S432D,S433D-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR1268 | Gln3S437D,L438D,M439D-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |
| pRR1270 | Gln3S504E-Myc | 5'-AACAGATCTGGATGAAGATTTACTGGAACTTGGATGGTTGCAATTTGCTGCAATTTGCT-3' |
|         |                     | 5'-CATGGAATCTCTGCTATGCTCTTCAAATATTAG-3' |

(continued)
itself. Following this reasoning, we localized a Gln3-mTor1 interacting site to 17 Gln3 residues with a predicted propensity to fold into an amphipathic α-helix (Kulkarni et al. 2001; Carvalho and Zheng 2003; Rai et al. 2013). When this Gln3-mTor1 interaction site was altered, rapamycin no longer elicited nuclear Gln3 localization, but the Gln3 response to poor, or limiting, nitrogen remained fully intact; it was like wild type (Rai et al. 2013). However, cytoplasmic Gln3 sequestration was only partially diminished, which indicated that the Gln3-mTor1 interaction site was not acting alone to sequester Gln3 in the cytoplasm. N-terminal of the mTor1 interacting domain, we identified a larger domain specifically required for a Gln3 response to rapamycin-treatment, but not the mTor1-Gln3 interaction (Rai et al. 2014). Importantly, aspartate, but not alanine, substitutions throughout the 80-residue domain uniformly abolished rapamycin-responsiveness, but did not affect either cytoplasmic Gln3 sequestration or its response to derepressive nitrogen sources such as proline or allantoin.

Strikingly, none of the above mutant studies identified an effect on Msx-elicited nuclear Gln3 localization. This was disturbing because glutamine was postulated to positively control mTor activity, and thereby Gln3 localization and function (Crespo et al. 2002). However, dispensability of Gtr-Ego complex components for maintaining cytoplasmic Gln3 sequestration in nitrogen excess other than the Ure2 binding site, and one that is independent of responses to rapamycin or Msx. We now report a potential candidate for this site in an unexplored region N-terminal of the sites required for rapamycin-responsiveness and mTor1-binding. It is a highly conserved 15-residue serine/threonine-rich (12 of 15 residues) region flanked by basic residues. Alteration of these serine residues partially abolished cytoplasmic sequestration of Gln3-Myc13, but did not affect its responses to rapamycin, Msx treatment, or limiting nitrogen. The fact that the rapamycin- and NCR-responsiveness of Gln3-Myc13 remained intact when aspartate or alanine was substituted for these serines argues that they are not the targets of rapamycin-activated Sit4 phosphatase, or limiting nitrogen, and hence represent a novel nitrogen-responsive target in Gln3 that is not part of the mTorC1-Sit4 or Ure2-mediated pathways. Importantly, alteration of these sites, combined with substitutions that destroy the Gln3-mTor1 interaction site, additively and almost completely abolished cytoplasmic Gln3-Myc13 sequestration. Thus, we have developed another tool needed to isolate and deconvolve the individual mTorC1-dependent and -independent regulatory pathways that act cumulatively to control cytoplasmic Gln3 sequestration.

In all of the above investigations, an important Gln3 site has been conspicuously missing—one uniquely required for cytoplasmic sequestration in nitrogen excess other than the Ure2 binding site, and one that is independent of responses to rapamycin or Msx. We now report a potential candidate for this site in an unexplored region N-terminal of the sites required for rapamycin-responsiveness and mTor1-binding. It is a highly conserved 15-residue serine/threonine-rich (12 of 15 residues) region flanked by basic residues. Alteration of these serine residues partially abolished cytoplasmic sequestration of Gln3-Myc13, but did not affect its responses to rapamycin, Msx treatment, or limiting nitrogen. The fact that the rapamycin- and NCR-responsiveness of Gln3-Myc13 remained intact when aspartate or alanine was substituted for these serines argues that they are not the targets of rapamycin-activated Sit4 phosphatase, or limiting nitrogen, and hence represent a novel nitrogen-responsive target in Gln3 that is not part of the mTorC1-Sit4 or Ure2-mediated pathways. Importantly, alteration of these sites, combined with substitutions that destroy the Gln3-mTor1 interaction site, additively and almost completely abolished cytoplasmic Gln3-Myc13 sequestration. Thus, we have developed another tool needed to isolate and deconvolve the individual mTorC1-dependent and -independent regulatory pathways that act cumulatively to control cytoplasmic Gln3 sequestration.

![Figure 2 Reproducibility of the data in this work. The histograms represent the means of the eight localization experiments contained in this work. They were performed over 4 yr, measuring Gln3-1,730-Myc13 localization in wild-type JK9-3da transformed with pRR536; error bars represent SD around these means.](image-url)
were performed as described in Materials and Methods. The length of the Gln3 proteins assayed appear above the plasmid numbers. Black dots indicate positions of major species. (A) pRR536, (B) pRR614, (C) pRR622, (D) pRR613, and (E) pRR609.

Figure 3 Gln3-Myc<sup>13</sup> phosphorylation profiles in transformants containing wild type (pRR536) and C-terminal gln3 truncation mutants. Cells were cultured in untreated YNB-glutamine (Gln) or proline (Pro) medium; rapamycin (+Rap) was added where indicated. Western blots

---

**MATERIALS AND METHODS**

*Saccharomyces cerevisiae* wild type, JK9-3da (MATa, leu2-3,112, ura3-52, trp1, his4, mel1, HMLa) or gln3Δ, KHC2 (MATa, lys2, ura3, gln3Δ::KanMX) strains were transformed with wild type and mutant plasmids carrying gln3 amino acid substitutions. JK9-3da is the parent of TB50, which is the parent of TB123. TCY1 is the parent of KHC2. Unless indicated otherwise, JK9-3da was used as the transformation recipient. Fresh transformants were then analyzed for intracellular Gln3-Myc<sup>13</sup> distribution. Growth conditions were those described in Tate et al. (2009). Cultures (50 ml) were grown to mid-log phase (A<sub>600nm</sub> = 0.5) in YNB (without amino acids or ammonium sulfate) minimal medium that contained the indicated nitrogen source at a final concentration of 0.1%. Appropriate supplements (120 μg/ml leucine, 20 μg/ml histidine and tryptophan) were added to the medium as necessary to cover auxotrophic requirements. Where indicated, cells were treated with 200 ng/ml rapamycin (+ Rap) for 20 min, or 2 mM methionine sulfoximine (+ Msx) for 30 min. For rapamycin resistance assays, the medium was solid synthetic complete (SC), with or without 50 ng/ml rapamycin.

**Plasmid constructions**

gln3 amino acid substitution mutants were constructed using standard PCR-based methods, and the primer sets in Table 1. The Myc<sup>13</sup> and ADH1 transcriptional terminator were derived from pKA62 (Kulkarni et al. 2006). The template for all of the constructions, unless otherwise indicated, was pRR536, which contained the wild-type *GLN3* gene, including its native promoter, fused in frame with Myc<sup>13</sup> at the *GLN3* translational stop codon. All of the constructs were confirmed by DNA sequencing (University of Tennessee Health Science Center Molecular Resource Center DNA sequencing facility).

**Indirect immunofluorescence microscopy and intracellular Gln3-Myc<sup>13</sup> distribution**

Cell collection and immunofluorescent staining were performed as previously described (Cox et al. 2004a, 2004b; Tate et al. 2006; Georis et al. 2008; Tate et al. 2009). Cells were imaged with a Zeiss Axioplan 2 imaging microscope, 63 × and 100 × Plan-Apochromat 1.40 oil objectives at room temperature. Images were captured by a Zeiss Axio camera, and AxioVision 3.0 and 4.8.1 (Zeiss) software. As reasoned in Rai et al. (2013), it is not possible to objectively determine the intracellular distribution of a protein from images of subjectively chosen fields containing a few cells unless the protein is confined exclusively to a single cellular compartment, i.e., cytoplasmic only or nuclear only. Gln3 is often simultaneously located in both cellular compartments. Therefore, we quantified intracellular Gln3 distribution by manually scoring Gln3-Myc<sup>13</sup> localization in 200 or more cells in multiple, randomly chosen fields. Scoring was performed exclusively using unaltered, primary .zvi image files generated by the camera, and viewed with Zeiss AxioVision 3.0 and 4.8.1 software. Cells were classified into one of three categories: cytoplasmic (cytoplasmic Gln3-Myc<sup>13</sup> fluorescence only; red bars), nuclear-cytoplasmic (Gln3-Myc<sup>13</sup> fluorescence appearing in the cytoplasm as well as colocalizing with DAPI-positive material, DNA; yellow bars), and nuclear (Gln3-Myc<sup>13</sup> fluorescence colocalizing only with DAPI-positive material; green bars). "Standard" images, that depict the characteristics of these categories, appear in Figure 6 in Tate et al. 2009. All conclusions in this work were based on these quantitative data.

The precision of our scoring has been repeatedly documented (Tate et al. 2006, 2010; Tate and Cooper 2007). Since wild-type controls accompanied all of the experiments presented below, these data were...
used to assess the reproducibility of our assays under all of the growth conditions analyzed. Data depicted in Figure 2 represent the means of eight experiments performed over 4 yr, measuring Gln3-730-Myc13 localization in wild-type JK9-3da transformed with pRR536; error bars represent the SD around these means.

Images accompanying the histograms in subsequent figures were chosen on the basis that they exhibited intracellular Gln3-Myc13 distributions as close as possible to those observed in the quantitative scoring, and are for illustrative purposes only. The images (after conversion from .zvi to .tif files) were processed in the following way using Adobe Photoshop and Illustrator programs: (i) Any alteration of an image was uniformly applied to the entire image presented. (ii) The only alteration of the images was to decrease the background fluorescence due to leak-through light not removed by the barrier filter of the microscope. This avoided any change or loss in cellular detail relative to what was observed in the microscope. The alterations were nearly the same from one image to another, but were not rigorously identical because the amount of leak-through fluorescence was not identical from one image to another.
Western blots

Western blots were performed as described earlier (Tate et al. 2009; Rai et al. 2013).

Data availability

Following publication, we will expeditiously share all cited strains and plasmids emanating from work supported by this grant with other investigators (for noncommercial use only) upon request. This will be done in accordance with NIH guidelines.

RESULTS

Gln3-Myc\(^{13}\) phosphorylation profiles of truncation mutants

Previously reported data predict the existence of a unique, rapamycin-independent, Gln3 site required for its response to the cell’s overall nitrogen supply, i.e., NCR. To search for this site, we compared the gross phosphorylation profiles of large Gln3-Myc\(^{13}\) truncations in rapamycin-treated cells, and those provided with a repressive (glutamine) vs. a derepressive (proline) nitrogen source (Figure 3) (Rai et al. 2013, 2014). Wild-type Gln3\(_1\)\(\text{--}730\)-Myc\(^{13}\), and a Gln3\(_1\)\(\text{--}600\)-Myc\(^{13}\) truncation, yielded three species in western blots (see black dots in each panel): the amount of the most rapidly migrating Gln3 species increased at the expense of the middle species; a normal response to rapamycin (Figure 3, A and B). As lower migrating upper species appeared only in proline-grown cells (Figure 3B). Three species were also present in a Gln3\(_1\)\(\text{--}584\)-Myc\(^{13}\) truncation, but the most rapidly migrating species no longer changed in intensity when rapamycin was added (Figure 3C). With a Gln3\(_1\)\(\text{--}542\)-Myc\(^{13}\) truncation, the proline-responsive and middle species were both still present (Figure 3D). However, the third species corresponding to that obtained with rapamycin-treatment was abolished, thus supporting the conclusions of our earlier investigations that this region was required for a response to rapamycin (Rai et al. 2014). Finally, in a Gln3\(_1\)\(\text{--}497\)-Myc\(^{13}\) truncation, two bands were present, neither of which was proline-responsive (Figure 3E). The loss of the proline-response occurred at a position just N-terminal to...
residues previously shown to be specifically required for a response to rapamycin, 510–594 (Rai et al. 2014).

C-Terminal region of Gln3 is predicted to be highly disordered

The above observations raised the possibility that a Gln3 region required for its NCR-sensitive response might be situated N-terminal of Gln3 residue 510. Given that the two Gln3 regions previously shown to be required for stimulus-specific nuclear Gln3 localization were associated with residues exhibiting predicted propensities to fold into α-helices, we analyzed the secondary structure of this region with multiple programs including PrDos, and Protein DisOrder Prediction (http://prdos.hgc.jp/cgi-bin/top.cgi; Ishida and Kinoshita 2007).

Figure 7 (A–C) show the response of Gln3-Myc13 localization to substitution of amino acids in Gln3 region 450 to 473. The format of the experiments and presentation of the data were as in Figure 6.
The results were dramatic. Most of the C-terminal half of Gln3 exhibited a predicted probability that ranged from 50% to greater than 90% of being disordered (prediction false positive rate /C24 5%) (Figure 4). Further, this region of Gln3 contained a 65-residue region highly conserved among the 11 yeast species most related to S. cerevisiae (Figure 5A). A portion of this conserved region is rich in both basic amino acids and serine/threonine residues, characteristics of some protein kinase sites (Figure 5A). Given these observations, and the fact that nothing was known about the functional significance of Gln3 residues in this region, we prepared a series of full length Gln3-Myc\textsuperscript{13} (pRR680) in nitrogen-rich glutamine (A–D) or ammonia (E and F) medium. Aspartate substitutions (pRR682) elicited Gln3-Myc\textsuperscript{13} intracellular Gln3-Myc\textsuperscript{13} distributions that were indistinguishable from wild type. The experimental format and presentation of the data were as described in Figure 6.
Alteration of a region rich in hydrophobic, asparagine and glutamine residues has no effect on stimulus-specific Gln3 responses

The first region analyzed was between Gln3 residues 421 and 439. It contained 28% hydrophobic, and 32% asparagine/glutamine residues. We replaced two or three hydrophobic residues in each of three constructs with charged aspartate residues [Gln3L421D,V423D-Myc13 (pRR1264); Gln3F430D,S432D,V433D-Myc13 (pRR1266); Gln3V437D,L438D,M439D-Myc13 (pRR1268)], reasoning that, if this region interacted with other proteins, or its secondary structure was needed for a particular function, these alterations would damage it. In all three substitution mutants, Gln3-Myc13 localization was indistinguishable from wild type, irrespective of whether we assessed glutamine- vs. proline-grown cells, or cells treated with rapamycin or Msx (Figure 6, C and D, A and B, and E and F, respectively). The same result was observed when we substituted aspartate for the hydrophobic residues between Gln3 residues 450 and 465 [Gln3N450D,F451D-Myc13 (pRR1331); Gln3L459D,L464D,M465D-Myc13 (pRR1323)] (Figure 7, left half).
Gln3 region, predicted to be disordered, is required for cytoplasmic Gln3 sequestration under repressive growth conditions

We then shifted our attention to Gln3469–499, a region predicted to be disordered (Figure 4, 90%) and exhibiting conservation among related species. The first pair of mutants constructed were Gln3S469D,T471D,T473D-Myc13 (pRR962) and Gln3S469A,T471A,T473A-Myc13 (pRR964) (Figure 5B). These choices derived from an earlier phosphoproteomics report that these residues were phosphorylated (Swaney et al. 2013). The aspartate and alanine substitutions, however, had no effect on Gln3-Myc13 localization, irrespective of the growth conditions employed (Figure 7, right half). In summary, the above constructs indicated that integrity of the region between Gln3 residues 421 and 473 was not demonstrably necessary for wild type regulation of Gln3 localization.

The next construct, however, was much more informative. We substituted aspartate (pRR682) or alanine (pRR680) for the center eight serine residues in the serine/threonine/basic amino acid-rich region of Gln3. Substitution of alanines for the center eight serine residues in the serine/threonine/basic amino acid-rich region of Gln3 reduces cytoplasmic sequestration of Gln3-Myc13 (pRR1040) in nitrogen-rich glutamine medium (A–D) and largely abolishes it in ammonia medium (E and F). Aspartate substitutions (pRR1043) elicited Gln3-Myc13 intracellular distributions that were indistinguishable from wild type. The experimental format and presentation of the data were as described in Figure 6.
residues situated between Gln3 positions 477 and 497 (Figure 8). These serines are embedded in the conserved basic/serine-rich portion of this region (Figure 5A). Aspartate substitutions had little to no demonstrable effect on Gln3-Myc13 localization. It was virtually wild type in all conditions assayed (Figure 8, pRR682). In contrast, substituting alanine for these serines strikingly diminished the ability of the cell to sequester Gln3-Myc13 in the cytoplasm of glutamine-grown cells. In fact, the intracellular distribution of Gln3-Myc13 in a glutamine-grown pRR680 transformant was almost the same as a similarly grown wild-type transformant treated with rapamycin, or one in which the Gln3-mTor1 interaction site was abolished (Figure 8B, compare W.T. Gln + Rap with pRR680 Gln) (Rai et al. 2013). This diminished ability for cytoplasmic sequestration was reflected in correspondingly greater nuclear Gln3-Myc13 localization in rapamycin-treated cells (Figure 8, A and B, pRR680) and those grown in derepressive proline media (Figure 8, C and D, pRR680). The greatest effect, however, was observed in ammonia-grown cells, in which Gln3-Myc13 was nearly undetectable in the cytoplasm, or the nuclear-cytoplasmic scoring category, in a substantial majority of the cells (Figure 8, E and F).

Three characteristics of the pRR680 substitution mutant merit emphasis: (i) it retained its ability to respond to rapamycin, arguing that these residues were not required for a response to rapamycin inhibition of TorC1 kinase. (ii) As extensive as the alanine substitutions were in this region of Gln3, they failed to totally abolish the ability of Gln3-Myc13 to be retained in the cytoplasm when cells were grown in repressive medium. (iii) Neither aspartate nor alanine substitutions in this region had any effect on nuclear Gln3-Myc13 localization in Msx-treated cells, just as has occurred in all of the Gln3 C-terminal alterations previously reported (Figure 8, E and F) (Rai et al. 2013, 2014). In pRR680, however, the fold-effect of Msx addition was small because Gln3-Myc13 was already mostly nuclear.

The strength of the serine-to-alanine substitution phenotype prompted us to further localize the residues upon which this effect depended. To this end, we substituted aspartate or alanine for four serine residues contained in an RRSSRSS repeat (Gln3S479D,S480D,S483D,S484D-Myc13, pRR678; Gln3S479A,S480A,S483A,S484A-Myc13, pRR676) (Figure 9). Here, as with pRR680, the aspartate substitutions yielded a wild type phenotype (Figure 9, pRR678). In contrast, alanine substitutions yielded a similar, but somewhat muted, version of the phenotype observed with the 13 substitution construct (Figure 9, pRR676). Cytoplasmic Gln3-Myc13 sequestration decreased by about half in glutamine-grown cells when compared to wild type (Figure 9, A and B, and C and D). Although nuclear Gln3-Myc13 localization clearly increased in ammonia-grown cells, the shift was also not as dramatic as with pRR680.

We next substituted the center eight serines/threonines between Gln3 residues 485 and 493 (pRR1040 and pRR1043). These residues were not flanked by basic amino acids (Figure 5B). Alteration of these residues yielded results similar to those just described for plasmids pRR678 and pRR676 (Figure 10). So they too contributed to the overall diminishment of cytoplasmic Gln3-Myc13 sequestration, but again were insufficient to achieve the robust phenotype exhibited by the pRR680 mutant. Therefore, while alteration of serine/threonine residues throughout this region significantly contributed to the loss of cytoplasmic Gln3-Myc13 sequestration, it appeared that most or all had to be altered to achieve a maximum effect.

**Alanine substitutions in serine-rich region alter the Gln3-Myc13 phosphorylation profile**

The observation that serine to alanine substitutions in the serine-rich region of Gln3 (pRR680) largely abolished cytoplasmic Gln3-Myc13 localization prompted us to query whether this result might be associated with an altered ability to phosphorylate Gln3. We particularly wanted to know whether these alterations affected rapamycin-elicited Gln3 dephosphorylation. To this end, we grew four of the above mutants (pRR682, pRR680, pRR678, and pRR676) in proline or glutamine medium, and further treated glutamine-grown cells with rapamycin (Beck and Hall 1999; Cox et al. 2004a).

In all four cases, the most rapidly migrating Gln3-Myc13 species increased in rapamycin-treated cells (Figure 11, A–D, lanes 1, 2, lowest black dot). This indicated that rapamycin-elicited Gln3-Myc13 dephosphorylation was unaffected by either the aspartate or alanine substitutions, supporting the conclusion reached from the Gln3-Myc13 localization data. In contrast, the Gln3-Myc13 phosphorylation profiles observed with serine to aspartate substitutions (pRR682 and pRR678) differed from those obtained with the alanine substitutions (pRR680 and pRR676) (Beck and Hall 1999; Cox et al. 2004a). Slower migrating Gln3-Myc13 species were observed in untreated cells containing the aspartate substitutions, but were missing in those containing the alanine substitutions (Figure 11, uppermost black dot).

**Alterations of sequences homologous to protein kinase target sites are without effect**

Two short sequences containing basic and serine residues observed in some protein kinase target sites were situated within the region covered by the 13 substitutions in plasmids pRR682 and pRR680. To specifically determine whether these sites contribute to the regulation of Gln3 localization, we substituted aspartate or alanine for the serines contained in them. The first two serines analyzed were Gln3S479D,S480D-Myc13, pRR1172 and Gln3S479A,S480A-Myc13, pRR1178). Gln3-Myc13 localization in these substitution mutants was indistinguishable from wild type (Figure 12, left side). We then created aspartate and alanine substitutions at Gln3S496D,S497D-Myc13 (pRR1080) and Gln3S496A,S497A-Myc13 (pRR1173). The only convincing effect the alanine substitutions elicited was in ammonia-grown cells (Figure 12). This argued that they participated in cytoplasmic Gln3 sequestration, but in only a minor way.
Serine to alanine substitutions in the Gln3 RRSSRRSS sequence generate rapamycin hyper-sensitivity

The above data generated a testable prediction. If serines in the Gln3477–497 region were truly required for cytoplasmic sequestration, then replacing them with alanine should increase the rapamycin sensitivity of the mutant transformants. Recall that cytoplasmic Gln3 sequestration is lost in ure2Δ mutants, where Gln3 is constitutively nuclear and the mutants are hypersensitive to rapamycin (Bertram et al. 2000).

Figure 12 (A–D) Alanine (pRR1178 and pRR1173) or aspartate (pRR1172 and pRR1180) substitutions for serine residues in the serine/threonine/basic amino acid-rich region of Gln3 with homology to known protein kinase phosphorylation sites. The experimental format and presentation of the data were as described in Figure 6.

Serine to alanine substitutions in the Gln3 RRSSRRSS sequence generate rapamycin hyper-sensitivity

The above data generated a testable prediction. If serines in the Gln3477–497 region were truly required for cytoplasmic sequestration, then replacing them with alanine should increase the rapamycin sensitivity of the mutant transformants. Recall that cytoplasmic Gln3 sequestration is lost in ure2Δ mutants, where Gln3 is constitutively nuclear and the mutants are hypersensitive to rapamycin (Bertram et al. 2000).
In contrast, \( gln3 \Delta \) mutants are rapamycin resistant. Therefore, we assessed the rapamycin sensitivity of our transformants. All of the mutant transformants, with two important exceptions, were no more rapamycin-sensitive than wild-type cells containing pRR536 (Figure 13). The first exception was with pRR680, containing the 13 serine/threonine to alanine substitutions in the \( Gln3^{477-497} \) region. The second, and more important, exception was with pRR676, in which the repeated RRSSRRSS was changed to RRAAR-RAA. Both constructs yielded highly rapamycin-sensitive transformants and, notably, they were equivalently rapamycin sensitive. The eight substitutions in pRR1043 adjacent to the RRSSRRSS sequence did not alter rapamycin sensitivity. Finally it is worth mentioning that none of the other substitution mutants, with the possible exception of pRR682, increased rapamycin resistance of transformants containing them as would be expected if they had adversely affected Gln3-mediated transcription.

### Alteration of the serine-rich region and the Gln3-mTor1 interaction site cumulatively abolishes cytoplasmic Gln3 localization

During identification of the Gln3-mTor1 interaction site, we noticed that alteration of that site not only rendered Gln3 localization immune to the effects of rapamycin treatment, but also partially abolished its cytoplasmic sequestration in nitrogen-replete conditions. While this suggested that Gln3 localization was probably controlled by the cumulative participation of multiple independent pathways, there was no way of directly testing that hypothesis. Discovering that alteration of the \( Gln3^{477-493} \) serine-rich region also partially abolished cytoplasmic Gln3 sequestration without affecting its response to rapamycin afforded an opportunity of doing so. To this end, we constructed a double mutant consisting of the alterations contained in pRR680 and those in pRR850, which destroys the Gln3-mTor1 interaction site (Rai et al. 2013). As shown in Figure 14, the two single mutants exhibited remarkably similar phenotypes, except that Gln3-Myc\(^{13}\) localization responded to rapamycin treatment in cells containing pRR680, but not pRR850. Critically, cytoplasmic Gln3-Myc\(^{13}\) sequestration was only partially abolished in the single mutants provided with either glutamine or ammonia as sole nitrogen source. In sharp contrast, it was almost completely abolished in the double mutant transformant containing pRR1340 (Figure 14). Based on the degree of cytoplasmic Gln3-Myc\(^{13}\) localization in the single mutants relative to wild type, it is possible to predict the level of cytoplasmic Gln3-Myc\(^{13}\) in the double mutant if the mutated sites are acting additively. These levels are indicated with arrows and yellow lines in the responses of glutamine- or ammonia-grown cells containing pRR1340. The predicted and observed levels of cytoplasmic Gln3-Myc\(^{13}\) sequestration are nearly identical.

### Alteration of conserved proline-rich sequence affects both Gln3-Myc\(^{13}\) cytoplasmic sequestration and rapamycin response

At the C-terminus of the highly conserved serine- and basic amino acid-rich region was a nine residue sequence in which prolines alternated with other residues, i.e., VPILPKPSP. To investigate this region, we substituted glutamate for the leucine or lysine residues in this region...
Both substitutions markedly decreased the ability of rapamycin to elicit nuclear Gln3-Myc\textsuperscript{13} localization (Figure 15, A and B). This phenotype contrasted with the wild-type responses of aspartate substitutions in the serine-rich region of Gln3 (Figure 6 and Figure 7 compared with Figure 15, C–F). Consistent with all of the earlier rapamycin-insensitive phenotypes, these alterations had no demonstrable effect on the ability of Msx to elicit high nuclear Gln3-Myc\textsuperscript{13} localization (Figure 15, E and F). Equally important, cytoplasmic Gln3-Myc\textsuperscript{13} sequestration was fully intact in both of these mutants. These results slightly extended the contiguous Gln3 domain required for a robust response to rapamycin.

**DISCUSSION**

Experiments presented in this work define a unique Gln3 17 amino acid peptide (Gln3\textsubscript{477-493}) that is required to sequester Gln3-Myc\textsuperscript{13} in the cytoplasm when cells are growing in nitrogen-rich medium (Figure 16). The site consists of a highly conserved serine/threonine-rich (12/15 residues) sequence flanked on either side by basic residues. Somewhat...
surprisingly, this region is not required for a Gln3 response to limiting nitrogen, rapamycin inhibition of mTorC1, or Msx inhibition of glutamine synthetase and ensuing glutamine starvation. Within this peptide is a repeated sequence: RRSSRSS. When alanines are substituted for the four serines in this sequence (pRR676), a phenotype similar to that of substituting all 13 serine/threonine residues of Gln3_{477-493} (pRR680) was obtained. We speculate that the serine and threonine residues in Gln3_{477-493} are phosphorylated in cells provided with excess nitrogen, because substitution of a phosphorylation mimic, aspartate (pRR682 and pRR678), yielded the same level of cytoplasmic Gln3-Myc^{13} sequestration in nitrogen-rich medium as wild type, whereas alanine substitutions that cannot be phosphorylated yielded the mutant phenotype, i.e., loss of cytoplasmic Gln3-Myc^{13} sequestration and rapamycin hypersensitivity (pRR680 and pRR676). Further, the slowest migrating Gln3-Myc^{13} species in western blots of the aspartate substituted mutants cited above was lost when alanine was substituted for these serines. The most slowly migrating Gln3-Myc^{13} species has been repeatedly shown to be the one that is most phosphorylated. The Gln3 site(s) and process(es) that control the phosphorylation of these residues remains a mystery.

Data presented above demonstrate that serines/threonines in Gln3_{477-493} must not only be capable of being phosphorylated, but also must act in concert with Gln3 sites phosphorylated by mTorC1 for Gln3-Myc^{13} to be effectively sequestered in the cytoplasm, as supported by the additive phenotypes of pRR850, pRR680, and pRR1340. However, the combined phosphorylation of these two targets is still insufficient to fully determine whether Gln3 enters the nucleus or is retained in the cytoplasm. Otherwise, the Gln3 localization in the single and double mutant transformants just cited should not have responded as they did to limiting nitrogen (proline grown), or Msx treatment. Further, also note that cytoplasmic Gln3-Myc^{13} sequestration is still not totally abolished even in the double mutant transformant growing in glutamine medium (Figure 14, pRR1340). In this regard it is pertinent to recall the important roles played by Ure2, and the influence of glutamine, on the course of events Gln3 follows once it is within the nucleus (Rai et al. 2015). What present and previously reported data do convincingly demonstrate is the presence of multiple distinctly regulated targets on the Gln3 molecule, which, by inductive reasoning, support the conclusion that nitrogen-responsive Gln3 localization and function are controlled by multiple, independent regulatory pathways.

One might conclude that Gln3_{477-493} contains the serines phosphorylated by mTor1, following its interaction with the Gln3_{466-470} site, because alteration of this site also results in a partial loss of cytoplasmic Gln3 sequestration (Rai et al. 2013). We do not favor this interpretation because: (i) abolishing the Gln3-mTor1 interaction site also abolished the ability of Gln3 to respond to rapamycin inhibition of mTorC1 (Rai et al. 2013), which did not occur in the Gln3_{477-493} mutants described in this work; and (ii) the electrophoretic mobility of Gln3-Myc^{13} increased when the mutant transformants were treated with rapamycin (Figure 11). By similar reasoning, if Gln3_{477-493} is phosphorylated, it is also unlikely to be the target of the rapamycin-elicted, Sit4-dependent Gln3 dephosphorylation and nuclear localization because a wild type rapamycin response occurred when aspartate was substituted for all of the serine residues in this site (Figure 8, Figure 9, and Figure 11). Further, Gln3-Myc^{13} only partially relocated to the nuclei of rapamycin-treated wild type cells. Yet when cytoplasmic Gln3-Myc^{13} retention was diminished by alanine substitutions in Gln3_{477-493}, nuclear Gln3 localization correspondingly increased. This is the behavior expected when multiple regulatory pathways operate cumulatively to bring about an overall result.

Finally, this is the first time that Gln3 has been reported to potentially be a disordered molecule. It is fascinating that the three specific regulatory sites identified in Gln3 thus far occur in regions of the molecule that are predicted to be disordered. In the most extreme case, the Gln3_{477-493} residues required for cytoplasmic Gln3 sequestration are also those that exhibit the greatest probability of being disordered (see residues between the arrows in Figure 4C). Consistent with the predicted probability of this region being disordered are the observations that extensive substitutions between the regulatory sequences documented thus far exhibit wild type phenotypes (Gln3_{421-473} in this work, and in Rai et al. 2013). Yet the regulatory sites themselves are highly sensitive to amino acid substitutions. If the overall region was highly structured, these inter-site substitutions would a priori be expected to exhibit something other than wild-type phenotypes. We speculate that the likelihood of the C-terminal region of Gln3 being disordered may be responsible for our ability to alter each of the individual regulatory sites in this region without telegraphing the effects of those alterations to the others. Only in the case of the short proline-rich region between the sites required for cytoplasmic Gln3 sequestration and rapamycin-responsiveness did we find substitutions that affected the functioning of two adjacent regulatory sites (Figure 15). We speculate that the core secondary structures of each of the sites that are the most sensitive to alteration (Figure 16) may initiate interactions with the regulatory molecules that target them followed by the acquisition of additional secondary structure emanating from the interactions themselves.
AKNOWLEDGMENTS
The authors are most grateful to Dr. Thomas Cunningham and the UTHSC Molecular Resource Center for performing the DNA sequencing analyses used to verify the mutant constructions we describe.

LITERATURE CITED
Beck, T., and M. N. Hall, 1999 The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors. Nature 402: 689–692.
Bertram, P. G., J. H. Choi, J. Carvalho, W. Ai, C. Zeng et al., 2000 Tripartite regulation of Gln3p by TOR, Ure2p, and phosphatases. J. Biol. Chem. 275: 35727–35733.
Binda, M., M.P. Péli-Gulli, G. Bonfils, N. Panachaud, J. Urban et al., 2009 The Van6 GEF controls TORC1 by activating the EGO complex. Mol. Cell 35: 563–573.
Binda, M., G. Bonfils, N. Panachaud, M. P. Péli-Gulli, and C. De Virgilio, 2010 An EGO-centric view of TORC1 signaling. Cell Cycle 9: 221–222.
Blinder, D., P. W. Coschigano, and B. Magasanik, 1996 Interaction of the GATA factor Gln3p with the nitrogen regulator Ure2p in Saccharomyces cerevisiae. J. Bacteriol. 178: 4734–4736.
Bonfils, G., M. Jaquenoud, S. Bontron, C. Ostrowicz, and C. Ungermann, et al., 2012 Leucyl-tRNA synthetase controls TORC1 via the EGO complex. Mol. Cell 46: 105–110.
Broach, J. R., 2012 Nutritional control of growth and development in yeast. Genetics 192: 73–105.
Cardenas, M. E., N. S. Cutler, M. C. Lorenz, C. J. Di Como, and J. Heitman, 1999 The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev. 13: 3271–3279.
Carvalho, J., and X. F. Zheng, 2003 Domains of Gln3p interacting with karyopherins, Ure2p, and the target of rapamycin protein. J. Biol. Chem. 278: 16878–16886.
Conrad, M., J. Schothorst, H. N. Kankipati, G. Van Zeebroeck, M. Rubio-Cardenas, M. E., N. S. Cutler, M. C. Lorenz, C. J. Di Como, and J. Heitman, 2003 Domains of Gln3p interacting with karyopherins, Ure2p, and the target of rapamycin protein. J. Biol. Chem. 278: 16878–16886.
Cooper, T. G., 1982 Nitrogen metabolism in Saccharomyces cerevisiae, pp. 39–99 in Molecular biology of the yeast Saccharomyces: metabolism and gene expression, edited by J. N. Strathern, E. W. Jones, and J. R. Broach. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
Cooper, T. G., 2004 Integrated regulation of the nitrogen-carbon interface, pp. 225–257 in Nutrient-induced responses in eukaryotic cells, Topics in Current Genetics, Vol. 7, chap. 9, edited by J. Winderickx, and P. M. Taylor. Springer-Verlag, Berlin-Heidelberg.
Cox, K. H., A. Kulkarni, J. J. Tate, and T. G. Cooper, 2004a Gln3 phosphorylation and intracellular localization in nutrient limitation and starvation differ from those generated by rapamycin inhibition of Tor1/2 in Saccharomyces cerevisiae. J. Biol. Chem. 279: 10270–10278.
Cox, K. H., J. J. Tate, and T. G. Cooper, 2004b Actin cytoskeleton is required for nuclear accumulation of Gln3 in response to nitrogen limitation but not rapamycin treatment in Saccharomyces cerevisiae. J. Biol. Chem. 279: 19294–19301.
Crespo, J. L., T. Powers, B. Fowler, and M. N. Hall, 2002 The TOR-controlled transcription activators Gln3N, RTG1, and RTG3 are regulated in response to intracellular levels of glutamine. Proc. Natl. Acad. Sci. USA 99: 6784–6789.
Di Como, C. J., and K. T. Arndt, 1996 Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases. Genes Dev. 10: 1904–1916.
Düvel, K., A. Santhanam, S. Garrett, L. Schneper, and J. R. Broach, 2003 Multiple roles of Tap42 in mediating rapamycin-induced transcriptional changes in yeast. Mol. Cell 11: 1467–1478.
Georis, I., J. J. Tate, T. G. Cooper, and E. Dubois, 2008 Tor pathway control of the nitrogen-responsive DAL5 gene bifurcates at the level of Gln3 and Gat1 regulation in Saccharomyces cerevisiae. J. Biol. Chem. 283: 8919–8929.
Hardwick, J. S., F. G. Kuruvilla, J. K. Tong, A. F. Shamji, and S. L. Schreiber, 1999 Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. USA 96: 14866–14870.
Ishida, T., and K. Kinoshita, 2007 PrDos: prediction of disordered protein regions from amino acid sequence. Nucleic Acids Res. 35: W460–W464 Web Server issue.
Jeong, J. H., K. H. Lee, Y. M. Kim, D. H. Kim, B. H. Oh et al., 2012 Crystal structure of the Gtr1p(GTP)-Gtr2p(GDP) protein complex reveals large structural rearrangements triggered by GTP-to-GDP conversion. J. Biol. Chem. 287: 29648–29653.
Jiang, Y., and J. R. Broach, 1999 Tor proteins and protein phosphatase 2A2A8 that regulate Tap42 in controlling cell growth in yeast. EMBO J. 18: 2782–2792.
Kulkarni, A. A., A. T. Abul-Hamd, R. Rai, H. El Berry, and T. G. Cooper, 2001 Gln3p nuclear localization and interaction with Ure2p in Saccharomyces cerevisiae. J. Biol. Chem. 276: 32136–32144.
Kulkarni, A., T. D. Buford, R. Rai, and T. G. Cooper, 2006 Differing responses of Gat1 and Gln3 phosphorylation and localization to rapamycin and methionine sulfoximine treatment in Saccharomyces cerevisiae. FEMS Yeast Res. 6: 218–229.
Laxman, S., B. M. Sutter, L. Shi, and B. P. Tu, 2014 Npr2 inhibits TORC1 to prevent inappropriate utilization of glutamine for biosynthesis of nitrogen-containing metabolites. Sci. Signal. 7(356): ra120.
Neklesa, T. K., and R. W. Davis, 2009 A genome-wide screen for regulators of TORC1 in response to amino acid starvation reveals a conserved Npr2/3 complex. PLoS Genet. 5(6): e1000515.
Panchaud, N., M. P. Péli-Gulli, and C. De Virgilio, 2013a SEACing the GAP that nEGOCiates TORC1 activation: evolutionary conservation of RapGAPase activity. Cell Cycle 12: 2948–2952.
Panchaud, N., M. P. Péli-Gulli, and C. De Virgilio, 2013b Amino acid deprivation inhibits TORC1 through a GTPase-activating protein complex for the Rag family GTPase Gtl1. Sci. Signal. 6(277): ra42.
Rai, R., J. J. Tate, D. R. Nelson, and T. G. Cooper, 2013 gln3 mutations dissociate responses to nitrogen limitation (nitrogen catabolite repression) and rapamycin inhibition of TorCl1. J. Biol. Chem. 288: 2789–2804.
Rai, R., J. J. Tate, K. Shammuganatham, M. M. Howe, and T. G. Cooper, 2014 A domain in the transcription activator Gln3 specifically required for rapamycin responsiveness. J. Biol. Chem. 289: 19099–19108.
Rai, R., J. J. Tate, K. Shammuganatham, M. M. Howe, D. Nelson et al., 2015 Nuclear Gln3 import is regulated by nitrogen catabolite repression whereas export is specifically regulated by glutamine. Genetics 201: 989–1016.
Rousselet, G., M. Simon, P. Ripoche, and J. M. Buhler, 1995 A second nitrogen permease regulator in Saccharomyces cerevisiae. FEBS Lett. 359: 215–219.
Spiewok, N., M. Guaderrama, J. A. Wohlschlegel, M. Ashe, J. R. Yates, 3rd et al., 2010 Npr2, yeast homolog of the human tumor suppressor NPR12, is a target of Grr1 required for adaptation to growth on diverse nitrogen sources. Eukaryot. Cell 9: 592–601.
Swaney, D. L., P. Beltrao, L. Storita, A. Guo, J. Rush et al., 2013 Global analysis of phosphorylation and ubiquitylation cross-talk in protein degradation. Nat. Methods 10: 676–682.
Tate, J. J., and T. G. Cooper, 2007 Stress-responsive Gln3 localization in Saccharomyces cerevisiae is separable from and can overwhelm nitrogen source regulation. J. Biol. Chem. 282: 18467–18480.
Tate, J. J., and T. G. Cooper, 2013 Five conditions commonly used to down-regulate tor complex 1 generate different physiological situations exhibiting distinct requirements and outcomes. J. Biol. Chem. 288: 27243–27262.
Tate, J. J., A. Feller, E. Dubois, and T. G. Cooper, 2006 Saccharomyces cerevisiae S4f1 phosphatase is active irrespective of the nitrogen source provided, and Gln3 phosphorylation levels become nitrogen-source-responsive in a s4f1-deleted strain. J. Biol. Chem. 281: 37980–37992.
Tate, J. J., I. Georis, A. Feller, E. Dubois, and T. G. Cooper, 2009 Rapamycin-induced Gln3 dephosphorylation is insufficient for nuclear localization: Sit4 and PP2A phosphatases are regulated and function differently. J. Biol. Chem. 284: 2522–2534.

Tate, J. J., I. Georis, E. Dubois, and T. G. Cooper, 2010 Distinct phosphatase requirements and GATA factor responses to nitrogen catabolite repression and rapamycin treatment in *Saccharomyces cerevisiae*. J. Biol. Chem. 285: 17880–17895.

Tate, J. J., I. Georis, R. Rai, F. Vierendeels, E. Dubois et al., 2015a GATA factor regulation in excess nitrogen occurs independently of Gtr-Ego complex-dependent TorC1 activation. G3 (Bethesda) 5: 1625–1638.

Tate, J. J., R. Rai, and T. G. Cooper, 2015b Nitrogen starvation and TorC1 inhibition differentially affect nuclear localization of the Gln3 and Gat1 transcription factors through the rare glutamine tRNA_{CUG} in *Saccharomyces cerevisiae*. Genetics 199: 455–474.

Wang, H., X. Wang, and Y. Jiang, 2003 Interaction with Tap42 is required for the essential function of Sit4 and type 2A phosphatases. Mol. Biol. Cell 14: 4342–4351.

Wu, X., and B. P. Tu, 2011 Selective regulation of autophagy by the Iml1-Npr2-Npr3 complex in the absence of nitrogen starvation. Mol. Biol. Cell 22: 4124–4133.

Yan, G., X. Shen, and Y. Jiang, 2006 Rapamycin activates Tap42-associated phosphatases by abrogating their association with Tor complex 1. EMBO J. 25: 3546–3555.

Zhang, T., M. P. Péli-Gulli, H. Yang, C. De Virgilio, and J. Ding, 2012 Ego3 functions as a homodimer to mediate the interaction between Gtr1-Gtr2 and Ego1 in the EGO complex to activate TORCl. Structure 20: 2151–2160.

*Communicating editor: C. S. Hoffman*